Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Fineline Cube Feb 11, 2026
Company Deals

uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases

Fineline Cube Feb 11, 2026
Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

Fineline Cube Feb 11, 2026
Company Drug

Takeda’s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist

Fineline Cube Feb 11, 2026
Company Deals

Leads Biolabs, Dianthus Therapeutics Announce Global Partnership for LBL‑047 Bispecific Fusion Protein

Fineline Cube Oct 17, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus Therapeutics...

Company Deals

NeuroGen Pharma Secures Exclusive Rights to Brexpiprazole Orally Disintegrating Film from Bocimed

Fineline Cube Oct 16, 2025

China‑based NeuroGen Pharma and Bocimed announced today that they have entered into an exclusive product‑transfer...

Company Drug

Chia Tai Tianqing Secures NMPA Approval for Phase III Trial of TQB2868 + Anlotinib in First‑Line mPDAC Therapy

Fineline Cube Oct 16, 2025

Chia Tai Tianqing, a wholly‑owned subsidiary of Sino Biopharmaceutical (HKG: 1177), announced today that the...

Company Drug

Lepu Biopharma Enrolls First Patient in Phase II Trial of MRG006A, the World’s First GPC3‑Targeting ADC

Fineline Cube Oct 16, 2025

Lepu Biopharma Co., Ltd. (HKG: 2157) announced today that it has successfully enrolled the first...

Company Deals

Jacobio Pharmaceuticals Secures 80% Equity Investment in Jacoray from Oceanpine Capital

Fineline Cube Oct 16, 2025

Jacobio Pharmaceuticals (HKG: 1167) today announced a capital‑increase and equity‑transfer agreement that will see Shanxi...

Policy / Regulatory

Zhejiang Authority Imposes Administrative Penalties on Dahongying Pharma for Substandard Fluorouracil Injection

Fineline Cube Oct 16, 2025

The Zhejiang Provincial Medical Products Administration announced that Ningbo Dahongying Pharmaceutical Co., Ltd. has been...

Company Drug

HELP Therapeutics Secures NMPA Approval for HiCM388, China’s First Cell‑Based Therapy for STEMI

Fineline Cube Oct 16, 2025

HELP Therapeutics Corp., a pioneer in cell‑based therapeutics, announced that the National Medical Products Administration...

Company

Abbott Reports Q3 2025 Revenue of $11.369 B, Up 6.9% YoY – Strong Growth Across Nutrition & Devices Segments

Fineline Cube Oct 16, 2025

Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September 30, 2025. For...

Company Deals

Haihe Biopharma Grants Taiho Pharmaceutical Exclusive License for Risovalisib in Japan

Fineline Cube Oct 16, 2025

China‑based Haihe Biopharma Co., Ltd. (the “Licensor”) announced today that it has entered into an...

Company Deals

Genesis Healthcare & MGI Sign Strategic MOU to Accelerate Precision Medicine in Japan

Fineline Cube Oct 16, 2025

Genesis Healthcare, a leading Japanese genetic‑testing provider, today announced the signing of a Memorandum of...

Company Deals

Nuance Pharma Partners with Stallergenes Greer to Launch Actair in China

Fineline Cube Oct 15, 2025

Nuance Pharma, an innovation-focused biopharmaceutical company, and Stallergenes Greer, a global leader in the allergy...

Policy / Regulatory

Pfizer CEO Bourla Highlights Benefits of China Biotech Collaborations at NY Gala

Fineline Cube Oct 15, 2025

Albert Bourla, CEO of Pfizer Inc. (NYSE: PFE), highlighted the benefits of collaborations between multinational...

Company Deals

Uni-Bio Science Partners with Sinovac to Expand Teriparatide Injection Globally

Fineline Cube Oct 15, 2025

Uni-Bio Science Group Limited (HKG: 0690), a China-based company, announced on September 12, 2025, that...

Company Deals

Adagene Expands Exelixis Collaboration to Include Third Target Using SAFEbody Technology

Fineline Cube Oct 15, 2025

Adagene Inc. (NASDAQ: ADAG) announced on September 16, 2025, that its collaboration and license agreement...

Company Deals

Ollin Biosciences Launches With $100M Funding to Advance Ophthalmology Pipeline

Fineline Cube Oct 15, 2025

Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company, announced its launch on September 16, 2025,...

Company Deals

Yanyin Tech and CirCode Biomed Forge Three-Year RNA Drug Development Partnership

Fineline Cube Oct 15, 2025

Yanyin Tech and Shanghai CirCode Biomed Co. Ltd. have announced a three-year strategic cooperation agreement...

Company Deals

China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases

Fineline Cube Oct 15, 2025

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into...

Company Deals

Livzon Launches China’s First Oral GnRH Antagonist for Multiple Indications

Fineline Cube Oct 15, 2025

Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the...

Company Deals

Pacific Shuanglin’s Controlling Stake Transferred to CNBG in RMB 4.7B Deal

Fineline Cube Oct 15, 2025

Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE: 000403), a China-based blood products company, announced that its...

Company Deals

Jingze Bio and CMS Subsidiary Partner to Commercialize Key Products in Reproduction and Ophthalmology

Fineline Cube Oct 15, 2025

On September 12, 2025, Jingze Biopharmaceutical (Hefei) Co., Ltd., based in China, and a subsidiary...

Posts pagination

1 … 50 51 52 … 623

Recent updates

  • Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III
  • Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication
  • Takeda’s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist
  • GSK’s RSV Vaccine Filing Accepted by NMPA for China Market Entry
  • uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Company Drug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

Company Drug

Takeda’s Oveporexton Wins FDA Priority Review for Narcolepsy Type 1, Potential First Orexin Agonist

Company Drug

GSK’s RSV Vaccine Filing Accepted by NMPA for China Market Entry

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.